AVDL · As filed with the SEC

Avadel Pharmaceuticals balance sheet, by fiscal year

The statement as Avadel Pharmaceuticals presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.

Consolidated Balance Sheets · USD thousands

USD thousands	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017
ASSETS
Current assets:
Cash and cash equivalents	51,371	31,167	73,981	50,708	71,722	9,774	9,325	16,564
Marketable securities	22,406	73,944	22,518	106,513	149,680	54,384	90,590	77,511
Accounts receivable, net	34,097	12,103	—	—	0	8,281	11,330	14,785
Inventories	20,298	10,380	—	—	0	3,570	4,770	6,157
Research and development tax credit receivable	—	1,322	2,248	2,443	3,326	2,107	—	—
Prepaid expenses and other current assets	6,036	5,286	2,096	32,826	38,726	4,264	8,836	8,958
Total current assets	134,208	134,202	100,843	192,490	263,454	82,380	124,851	123,975
Property and equipment, net	453	585	839	285	359	544	1,911	3,001
Operating lease right-of-use assets	1,702	2,591	1,713	2,652	2,604	3,612	—	—
Goodwill	16,836	16,836	16,836	16,836	16,836	18,491	18,491	18,491
Intangible assets, net	—	—	—	—	0	813	1,629	92,289
Research and development tax credit receivable	—	332	1,232	1,225	3,445	6,322	7,272	5,272
Income tax deferred charge	—	—	—	—	—	—	—	0
Other non-current assets	11,037	10,152	11,322	33,777	24,939	39,274	36,146	10,249
Total assets	164,236	164,698	132,785	247,265	311,637	151,436	190,300	253,277
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Current portion of long-term contingent consideration payable	—	—	—	—	0	5,554	9,439	25,007
Current portion of long-term debt	—	—	37,668	—	—	0	106	111
Current portion of long-term debt	—	0	—	—	—	—	—	—
Current portion of operating lease liability	582	934	960	900	474	645	—	—
Accounts payable	7,328	11,433	7,890	7,679	2,934	6,100	3,503	7,477
Deferred revenue	—	—	—	—	—	—	—	2,007
Deferred revenue	—	—	—	—	—	—	114	—
Accrued expenses	40,651	24,227	7,334	7,151	6,501	19,810	21,695	50,926
Income taxes	—	—	—	—	—	—	73	414
Other current liabilities	273	261	1,941	5,270	5,200	3,875	3,453	597
Total current liabilities	48,834	36,855	55,793	21,000	15,109	35,984	38,383	86,539
Long-term debt	—	—	91,614	142,397	128,210	121,686	115,734	156
Long-term contingent consideration payable, less current portion	—	—	—	—	0	11,773	19,401	73,918
Long-term debt	—	0	—	—	—	—	—	—
Long-term operating lease liability	1,122	1,690	780	1,707	1,840	2,319	—	—
Royalty financing obligation	35,249	32,760	—	—	—	—	—	—
Other non-current liabilities	5,183	5,654	5,743	3,917	4,212	8,873	14,002	7,084
Total liabilities	90,388	76,959	153,930	169,021	149,371	180,635	187,520	167,697
Shareholders’ equity:
Preferred shares, nominal value of $0.01 per share; 50,000 shares authorized; zero issued and outstanding at December 31, 2024 and 5,194 issued and outstanding at December 31, 2023	0	52	5	5	5	0	0	0
Ordinary shares, nominal value of $0.01 per share; 500,000 shares authorized; 96,518 issued and outstanding at December 31, 2024 and 89,825 issued and outstanding at December 31, 2023	965	898	628	586	583	429	427	414
Treasury shares, at cost, 0 and 5,407 shares held at December 31, 2020 and December 31, 2019, respectively	—	—	—	—	0	(49,998)	(49,998)	(22,361)
Additional paid-in capital	891,791	855,452	589,783	549,349	566,916	434,391	433,756	393,478
Accumulated deficit	(794,328)	(745,496)	(585,220)	(447,756)	(384,187)	(391,215)	(357,989)	(262,685)
Accumulated other comprehensive loss	(24,580)	(23,167)	(26,341)	(23,940)	(21,051)	(22,806)	(23,416)	(23,266)
Total shareholders’ equity	73,848	87,739	(21,145)	78,244	162,266	(29,199)	2,780	85,580
Total liabilities and shareholders’ equity	164,236	164,698	132,785	247,265	311,637	151,436	190,300	253,277

As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.